CATEGORY : Biomarkers

Life Science Market Reports

Our life science market intelligence products have been recognized by market insiders and outsiders alike for their accuracy, in-depth analysis, and unique insights.

Market Reports

A 2020 Look at 3 Trends in Immuno-Oncology Biomarkers

We recently added >300 new trials to our I/O biomarker clinical trial tracker, The I/O BioMAP, bringing our running total to ~2,700 studies, and providing new data that sheds light

How KKR Made a ~3x Return in 4 Years by Investing in Research Tools

  KKR made headlines late last year with the exit of their investment in LGC Group, a UK-based biochemical standards and reagents provider. Sources say KKR acquired LGC in December

Digital Health Democratizes Precision Medicine to Improve Population Health

  By definition, precision medicine treats the individual while public health focuses on population-level interventions. While public health and precision medicine efforts overlap, some experts argue that precision medicine advancements

The Follower’s Advantage: Cases in Life Science Research Tool Markets

The first mover’s advantage is a widespread concept in business. The idea is that a company can gain a competitive advantage by being the first to enter into an untapped

Evolution in the precision oncology landscape – Part 2 (Therapeutic Developments)

Over the past several months, we spoke to experts across the precision medicine landscape to understand some of the key changes and most impactful scenarios they expect in this space.

3 Machine Learning / Artificial Intelligence Trends In The Diagnostics Space For 2020 And Beyond

2019 was another strong year for machine learning and artificial intelligence within the diagnostic space, and the acceleration of progress in ML / AI is clearly going to continue within

Evolution in The Precision Oncology Landscape – Part 1 (Diagnostics Developments)

Over the past several months, we spoke to experts across the precision medicine landscape to understand some of the key changes and most impactful scenarios they expect in this space.

Pain Points, Unmet Needs, and Disruption in Precision Medicine – Part 1

DeciBio’s mission is to provide market intelligence and strategic insights that drive disruption and innovation in the precision medicine and life science industry. To this end, my colleague, Colin Enderlein,

Zolgensma and Drug Development in the Era of One-and-Done

On May 24th, the FDA approved a revolutionary treatment for children under two years old who have spinal muscular atrophy (SMA) type I – a debilitating condition resulting from a